Goldman Sachs on Acadia Pharmaceuticals (ACAD): 'We expect the stock to move lower on Tuesday given the results of the vote'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Neutral rating and $20.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
